DouglasJWecksteinMD

Oncology • Hooksett, NH

Principle Investigator Clinical Trials Program NH Oncology Hematology PA

Join to view full profile

Dr. Weckstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weckstein's full profile

Already have an account?

Office
200 Technology Dr
Hooksett, NH 03106
Phone+1 603-622-6484
Is this information wrong?

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Tufts Medical CenterResidency, Internal Medicine, 1986 - 1989
Virginia Commonwealth University School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 1988 - 2025
NH State Medical License 1998 - 2024
NY State Medical License 1995 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2014

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery Start of enrollment: 2006 Feb 01
Completed
Phase 2
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 2
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Start of enrollment: 2008 Mar 01
Completed
Phase 2
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Vitamin D and Breast Cancer Biomarkers in Female Patients Start of enrollment: 2010 Oct 01
Completed
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...
Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Da...> ;Journal of Clinical Oncology. 2024 Apr 1
1 citations
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag, Shaker R Dakhil, Philip J Stella, Douglas J Weckstein, Donald B Wender, Meredi...> ;The Oncologist. 2022 Apr 5
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
14 citations
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
64 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
4 citations
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.
Justin C. Brown, Michael H. Rosenthal, Chao Ma, Sui Zhang, Halla Sayed Nimeiri, Nadine Jackson McCleary, Thomas A. Abrams, Matthew B. Yurgelun, James M. Cleary, Dougla...> ;Cancers. 2020 Nov 20
112 citations
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE...
Kimmie Ng, Halla Sayed Nimeiri, Nadine Jackson McCleary, Thomas A. Abrams, Matthew B. Yurgelun, James M. Cleary, Douglas A. Rubinson, Deborah Schrag, Rebecca A. Miksad...> ;JAMA. 2019 Apr 9
86 citations
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Lori M. Minasian, William Kevin Kelly, Ann M. O'Mara, Andrea Denicoff, Drew K. Seisler, Pamela J. Atherton, Electra D. P...> ;JAMA Oncology. 2017 Aug 1
212 citations
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Andrew L. Himelstein, Jared C. Foster, James L. Khatcheressian, John D. Roberts, Drew K. Seisler, Paul J. Novotny, Rui Qin, Ronald S. Go, Stephen Grubbs, Tracey O'Conn...> ;JAMA. 2017 Jan 3
276 citations
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus ...
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay Harris, David W. Ollila, Ian E. Krop, Norah Lynn Henry, Douglas ...> ;Journal of Clinical Oncology. 2016 Sep 19
14 citations
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
Nan Lin, Davinia Shien Seah, Rebecca Gelman, Stephen DeSantis, Erica L. Mayer, Steven J. Isakoff, Pamela J. DiPiro, Ian E. Krop, Steven E. Come, Douglas Weckstein, Eri...> ;Breast Cancer Research and Treatment. 2013 May 5
62 citations
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Mari Nakabayashi, Lilian Werner, Kevin D. Courtney, Geoffrey Buckle, William Oh, Glen J. Bubley, Julia H. Hayes, Douglas Weckstein, Aymen Elfiky, Danny M. Sims, Philip...> ;BJU International. 2012 Dec 1
23 citations
Assessment of Perceived Cost to the Patient and Other Barriers to Clinical Trial Participation
Douglas J. Weckstein, Christian A. Thomas, Ivette F. Emery, Barbara F. Shea, Alison Fleury, Margaret E. White, Elizabeth Chase, Cindy Robinson, Stacey Frazier, Christi...> ;Journal of Oncology Practice. 2011 Sep 1
262 citations
Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401
Arti Hurria, Constance Cirrincione, Hyman B. Muss, Alice B. Kornblith, William T. Barry, Andrew S. Artz, Linda Schmieder, Rafat Ansari, William P. Tew, Douglas Weckste...> ;Journal of Clinical Oncology. 2011 Apr 1
72 citations
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
Charles L. Shapiro, Susan Halabi, V. Hars, L. Archer, Douglas Weckstein, Jeffrey J. Kirshner, William Sikov, Eric P. Winer, Harold J. Burstein, Clifford A. Hudis, Clau...> ;European Journal of Cancer. 2011 Mar 1
Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma.
Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA> ;J. Clin. Oncol.. 2009-05-20
Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results ...
Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, Winer EP, Hudis CA, Isaacs C, Weckstein D, Schilsky RL, Paskett E> ;J. Clin. Oncol.. 2008-05-20
Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy.
Periman PO, Sonpavde G, Bernold DM, Weckstein DJ, Williams A, Zhan F, Boehm KA, Asmar L, Hutson TE> ;J. Clin. Oncol.. 2008-05-20
1 citations
Neuroleptic malignant-like syndrome due to cyclobenzaprine?
Theoharis C. Theoharides, Harris Rs, Weckstein D> ;Journal of Clinical Psychopharmacology. 1995 Feb 1
37 citations
The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro.
Raymond E. Gibson, Douglas J. Weckstein, Elaine M. Jagoda, W. J. Rzeszotarski, Richard C. Reba, William C. Eckelman> ;Journal of Nuclear Medicine. 1984 Feb 1
21 citations
Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors.
Raymond E. Gibson, W. J. Rzeszotarski, William C. Eckelman, Elaine M. Jagoda, Douglas J. Weckstein, Richard C. Reba> ;Biochemical Pharmacology. 1983 Jun 15
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Sonpavde, G., Periman, P. O., Bernold, D., Weckstein, D., Fleming, M. T., Galsky, M. D., Berry, W. R., Zhan, F., Boehm, K. A., Asmar, L., Hutson, T. E.> ;Ann Oncol. 2010 Feb 01
ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.
Kelliher, M. A., Weckstein, D. J., Knott, A. G., Wortis, H. H., Rosenberg, N.> ;Oncogene. 1993 May
Join now to see all